Medical/Pharmaceuticals
ChomiX Biotech Announces millions of dollars Series Pre-A+ Financing to accelerate the development of Chemoproteomics Platform
NANJING, China, May 15, 2023 /PRNewswire/ -- Recently, ChomiX Biotech Co., Ltd. (hereinafter referred to as ChomiX), a leading biotechnology company focusing on the preclinical development of innovative small molecule drugs, announced the completion of millions of dollars Pre-A+ Financing by Tige...
2023-05-15 20:00
2757
Meihua International Medical Technologies Co., Ltd.'s Subsidiary to Attend and Showcase 12 New Products at the 87th China International Medical Equipment Fair
YANGZHOU, China, May 15, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that its wholly...
2023-05-15 19:30
2660
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)
Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of autoantibodies producing B-cells and plasma cells SAN DIEGO...
2023-05-15 19:00
3069
Zylox-Tonbridge to be Added to MSCI China All Shares Small Cap Index
HANGZHOU, China, May 15, 2023 /PRNewswire/ -- On May 12, MSCI, a leading provider of critical decision support tools and services for the global investment community, announced the results of theMay 2023 Index Review for the MSCI Equity Indexes. Zylox-Tonbridge (2190.HK, "the Company") is pleased...
2023-05-15 12:17
2949
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C...
2023-05-12 23:30
4882
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
SUZHOU, China, May 12, 2023 /PRNewswire/ -- Today, Crystal Pharmatech announced that the GMP manufacturing facility of their CDMO business unit – Crystal Formulation Services (CFS) has successfully passed a remote audit conducted by a US client. The audit, which lasted for four days, confirmed th...
2023-05-12 21:00
3345
Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center
CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™), announced today it has entered into a strategic collaboration agre...
2023-05-12 09:32
3043
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment ofrelapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Longer-term GC012F data in relapsed/refractory multip...
2023-05-12 05:28
3462
Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
SUZHOU, China, May 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatm...
2023-05-11 23:30
3549
CytoMed Therapeutics to Ring Nasdaq Closing Bell
SINGAPORE, May 11, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company") (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, will ...
2023-05-11 21:00
4618
Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements
MACAU, May 10, 2023 /PRNewswire/ -- From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023is being held at the Venetian Macau Convention and Exhibition Center. This year is the third consecutive year that Fosun Pharma (stock code: 600196....
2023-05-10 22:57
4471
Lunit to Present 16 Abstracts at the 2023 ASCO Annual Meeting
- Lunit and collaborators demonstrate the predictive value and analytical prowess of Lunit's AI-biomarker platform in a wide range of cancer types and clinical practices SEOUL, South Korea, May 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer di...
2023-05-10 13:44
3351
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today ...
2023-05-09 22:07
3675
Ubie collaborates with Google's Android platform "Health Connect (Beta)" as a launch partner in Japan
NEW YORK, May 9, 2023 /PRNewswire/ -- Ubie, Inc. (US Headquarters: 1460 Broadway,New York, Suite 10003, NY 10036; Co-Representative Directors: Yoshinori Abe and Kota Kubo; hereinafter referred to as "Ubie") has partnered with Google's Android platform, "Health Connect (Beta)," as one of the six ...
2023-05-09 21:00
3807
The First International Conference On Single-Cell And Spatial Omics is held in Guangzhou, China: the Golden Age of Single Cell Analysis
GUANGZHOU, China, May 8, 2023 /PRNewswire/ -- On April 16th 2023, the first International Conference on Single-cell and Spatial Omics (TICSSO-1) has come to a grand conclusion. The conference brings together on site over 2,000 professionals from academia, research and development, investment and ...
2023-05-09 12:27
2452
Singlera Genomics Receives FDA Breakthrough Device Designation for PDACatch, a Liquid Biopsy Assay for Pancreatic Cancer Detection in High-Risk Individuals
SAN DIEGO, May 8, 2023 /PRNewswire/ -- Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, today announced that it had received Breakthrough Device Designation from the Food and Drug Administration (FDA) for its PDACatch assay, a nov...
2023-05-08 22:00
2914
EmeTerm Anti Fatigue & Car Sickness Wristband Wins the IF and IDA Design Awards
VANCOUVER, BC, May 8, 2023 /PRNewswire/ -- Improving the driving experience of drivers and passengers has been one of the directions of innovation in the automotive industry for many years. To address motion sickness and driving fatigue, automakers are working to develop a variety of technologies...
2023-05-08 21:00
3329
PharmAbcine to participate in "BIO International Convention 2023"
DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023. Details...
2023-05-08 20:00
3807
Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China
HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, Hong Kong, and Macao). INBRIJA is indicated in the United ...
2023-05-08 19:30
2384
MEDICAL IP Is Creating Medical Digital Twins in Virtual Spaces, Powered by NVIDIA Omniverse
* MEDIP PRO, a real-time digital twin implementation solution based on medical imaging, is now connected to NVIDIA Omniverse * Maximize medical data scalability by sharing and simulating medical-imaging-based digital twins without time and space limitations SEOUL, South Korea and SANTA CLARA,...
2023-05-08 16:00
3664
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
7186
